*Other Operating Data Consensus Source: Bloomberg
More on Johnson & Johnson
- Johnson & Johnson To Acquire Protagonist? It’d Be A Good Deal To Make
- Johnson & Johnson: A Safe Haven That’s Quietly Becoming A Bit Overpriced
- Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
- Protagonist Therapeutics falls amid a report J&J deal price may be lower
- Johnson & Johnson Q3 earnings on deck: What to expect